Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > Warrant expiry announced

<< Previous

Bullboard Posts

Next >>

Comment by 294everon Dec 24, 2020 5:14pm

137 Views

Post# 32181746

RE:RE:RE:RE:RE:RE:Warrant expiry announced

Merry Xmas Pandora,
the VWAP numbers on the house are accurate. There is a formula for it , but not merely as straightforward as adding the prices and dividing days, but rest assured Algernons math is good. Hope this finds you and everyone healthy and well.

Merry Xmas

N

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China